GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Gross-Profit-to-Asset %

Elanix Biotechnologies AG (FRA:ELN) Gross-Profit-to-Asset % : -2.53% (As of Dec. 2018)


View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Elanix Biotechnologies AG's annualized Gross Profit for the quarter that ended in Dec. 2018 was €-0.29 Mil. Elanix Biotechnologies AG's average Total Assets over the quarter that ended in Dec. 2018 was €11.32 Mil. Therefore, Elanix Biotechnologies AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2018 was -2.53%.


Elanix Biotechnologies AG Gross-Profit-to-Asset % Historical Data

The historical data trend for Elanix Biotechnologies AG's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Gross-Profit-to-Asset % Chart

Elanix Biotechnologies AG Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.01 0.70 -12.36

Elanix Biotechnologies AG Semi-Annual Data
Dec08 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.52 0.39 -1.28 -2.53

Competitive Comparison of Elanix Biotechnologies AG's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Elanix Biotechnologies AG's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elanix Biotechnologies AG's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elanix Biotechnologies AG's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Elanix Biotechnologies AG's Gross-Profit-to-Asset % falls into.



Elanix Biotechnologies AG Gross-Profit-to-Asset % Calculation

Elanix Biotechnologies AG's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2018 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2018 )/( (Total Assets (A: Dec. 2017 )+Total Assets (A: Dec. 2018 ))/ count )
=-0.219/( (2.466+1.078)/ 2 )
=-0.219/1.772
=-12.36 %

Elanix Biotechnologies AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2018 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2018 )/( (Total Assets (Q: Jun. 2018 )+Total Assets (Q: Dec. 2018 ))/ count )
=-0.286/( (21.569+1.078)/ 2 )
=-0.286/11.3235
=-2.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2018) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Elanix Biotechnologies AG Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanix Biotechnologies AG (FRA:ELN) Business Description

Traded in Other Exchanges
N/A
Address
Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474
Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines